Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
This phase II study determined the efficacy and safety of alemtuzumab, a humanized anti-CD52 monoclonal antibody, delivered subcutaneously as first-line therapy, over a prolonged treatment period of 18 weeks in 41 patients with symptomatic B-cell chronic lymphocytic leukemia (B-CLL). Injections were...
Main Authors: | Lundin, J, Kimby, E, Björkholm, M, Broliden, P, Celsing, F, Hjalmar, V, Möllgård, L, Rebello, P, Hale, G, Waldmann, H, Mellstedt, H, Osterborg, A |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
2002
|
Títulos similares
-
Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
por: Lundin, J, et al.
Publicado: (2001) -
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
por: Hale, G, et al.
Publicado: (2004) -
The CAMPATH-1 antigen (CDw52).
por: Hale, G, et al.
Publicado: (1990) -
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
por: Hale, G, et al.
Publicado: (2002) -
In vivo 'purging' of residual disease in CLL with Campath-1H.
por: Dyer, M, et al.
Publicado: (1997)